Panion & Bf Biotech (TPE:1760) Ending Cash Position: NT$471 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1760 Panion & Bf Biotech Inc TPE:1760
75 GF Score
Price NT$56.40
GF Value NT$86.44
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Panion & Bf Biotech Ending Cash Position?

Panion & Bf Biotech TPE:1760 +0.18% 75 Ending Cash Position is NT$471 Mil as of Jun. 2026. GuruFocus rates TPE:1760 with a GF Score™ of 75/100 and a GF Value™ of NT$86.44 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Panion & Bf Biotech's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$471 Mil.

Panion & Bf Biotech's quarterly Ending Cash Position declined from Dec. 2025 (NT$460 Mil) to Mar. 2026 (NT$452 Mil) but then increased from Mar. 2026 (NT$452 Mil) to Jun. 2026 (NT$471 Mil).

Panion & Bf Biotech's annual Ending Cash Position increased from Dec. 2023 (NT$535 Mil) to Dec. 2024 (NT$558 Mil) but then declined from Dec. 2024 (NT$558 Mil) to Dec. 2025 (NT$460 Mil).

Panion & Bf Biotech Ending Cash Position Related Terms

Panion & Bf Biotech Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Panion & Bf Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panion & Bf Biotech Ending Cash Position Chart

Panion & Bf Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 279.10 464.26 534.63 558.37 460.32

Panion & Bf Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 522.23 379.98 460.32 451.62 471.42
TPE:1760
75GF Score
Panion & Bf Biotech Inc TPE:1760
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panion & Bf Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Panion & Bf Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=558.371+-98.055
=460

Panion & Bf Biotech's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=451.622+19.8
=471

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$471 Mil mean?
Panion & Bf Biotech (TPE:1760) has a Ending Cash Position of NT$471 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Panion & Bf Biotech and its competitors.
Is Panion & Bf Biotech's Ending Cash Position too high?
Panion & Bf Biotech's current Ending Cash Position is NT$471 Mil. Overall, Panion & Bf Biotech has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Ending Cash Position compare to ZTS?
Panion & Bf Biotech's Ending Cash Position of NT$471 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Panion & Bf Biotech and its competitors. Panion & Bf Biotech's current Ending Cash Position is NT$471 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$86.44, compared to a current price of NT$56.40 — trading 34.8% below its estimated fair value. The current Ending Cash Position is NT$471 Mil. Panion & Bf Biotech's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Ending Cash Position is NT$471 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?

Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued. The current stock price of NT$56.40 is trading 34.8% below its estimated GF Value™ of NT$86.44. GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1760:

  • Ending Cash Position: NT$471 Mil
  • GF Value™: NT$86.44 vs. price of NT$56.40 (34.8% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Panion & Bf Biotech Business Description

Address No. 3, Park Street, 16th Floor, Nangang District, Taipei, TWN, 11503
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
75GF Score

Get the complete analysis for TPE:1760

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$56.40
Price
NT$86.44
GF Value